| Literature DB >> 33803953 |
Pietro Valerio Foti1, Mario Travali1, Renato Farina1, Stefano Palmucci1, Maria Coronella1, Corrado Spatola1, Lidia Puzzo2, Rossella Garro2, Gaetano Inserra3, Gaia Riguccio3, Luca Zanoli4, Antonio Basile1.
Abstract
Background andEntities:
Keywords: Crohn’s disease; apparent diffusion coefficient; diffusion weighted imaging; fibrosis; magnetic resonance enterography; magnetic resonance imaging
Year: 2021 PMID: 33803953 PMCID: PMC8000737 DOI: 10.3390/medicina57030265
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
MRE protocol. Synoptic table summarizes the scanning parameters of MR pulse sequences. Coronal T1-weighted 3D gradient-echo liver acquisition with volume acceleration (LAVA) sequences with fat suppression were acquired before and after intravenous administration of paramagnetic contrast material (0.1 mmol/kg, followed by 20 mL of saline solution, both at a flow rate of 2 mL/s); in particular, the sequence was acquired at 60 and 120 s after contrast administration. An anti-peristaltic agent, scopolamine-N-butyl bromide (Buscopan® 20 mg; Boehringer Ingelheim, Milano, Italy), was administered intravenously just before post-contrast imaging to reduce peristaltic artifacts.
| MRI Protocol | Coronal T2W SSFSE | Coronal FIESTA | Coronal T2W Thick-slab SSFSE | Axial DWI SE EPI | Sagittal, Coronal, Axial T1W 3D GRE LAVA |
|---|---|---|---|---|---|
| Repetition time/Echo time (ms) | 705/90 | 4/1.7 | 2408/1103 | 3000/74 | 4.1/1.9 |
| Flip angle | 90° | 75° | 90° | 90° | 12° |
| Section Thickness (mm) | 6 | 6 | 70 | 8 | 3.4 |
| Interslice gap (mm) | 0.6 | 0.6 | — | 2 | 1.7 |
| Bandwidth (kHz) | 83.33 | 100 | 31.25 | 250 | 62.5 |
| Field of view (cm) | 44–48 | 44–48 | 44–48 | 42 | 44–48 |
| Matrix | 384 × 224 | 512 × 384 | 512 × 384 | 160 × 160 | 320 × 192 |
| N. of signal acquired | 0.57 | 1 | 1 | 2 | 0.7 |
| N. of images | 28 | 28 | 1 | 15 | 120 |
| Frequency direction | Right to left | Right to left | Right to left | Anterior to posterior | Superior to inferior |
| Acquisition time (s) | 24 | 22 | 2 | 27 | 23 |
| B-value (s/mm2) | — | — | — | 0–800 | — |
T2W = T2-weighted, T1W = T1-weighted, SSFSE = single-shot fast spin-echo, FIESTA = fast imaging employing steady-state acquisition, DWI = diffusion-weighted imaging, SE = spin-echo, EPI = echoplanar imaging, GRE = gradient-echo, LAVA = liver acquisition with volume acceleration.
Demographic data and medical therapy.
| Patient | Gender | Age | Smoker | Disease Duration | Therapy |
|---|---|---|---|---|---|
| Case 1 | M | 32 | former | 10 years 5 months | 5-ASA |
| Case 2 | M | 30 | active | 8 years 4 months | CS, IFX, ADA |
| Case 3 | F | 51 | no | 8 months | 5-ASA, CS |
| Case 4 | M | 45 | active | 1 years 5 months | 5-ASA, CS |
| Case 5 | F | 61 | active | 25 years 7 months | CS, IFX, ADA |
| Case 6 | M | 64 | former | 33 years | 5-ASA, CS |
| Case 7 | M | 36 | active | 5 years 9 months | 5-ASA |
| Case 8 | M | 58 | no | 11 years 5 months | 5-ASA, CS |
| Case 9 | M | 52 | active | 7 months | none |
| Case 10 | F | 48 | former | 1 years 4 months | 5-ASA, CS |
| Case 11 | M | 56 | no | 12 years 3 months | 5-ASA, CS |
| Case 12 | F | 35 | no | 5 years 10 months | 5-ASA, CS, ADA |
| Case 13 | M | 32 | no | 7 years 2 months | CS, IFX |
| Case 14 | F | 49 | former | 21 years 7 months | 5-ASA, IFX |
| Case 15 | F | 22 | no | 7 years 2 months | 5-ASA, AZA |
| Case 16 | F | 62 | former | 1 years 10 months | 5-ASA, CS |
| Case 17 | F | 63 | former | 1 years 6 months | none |
| Case 18 | M | 19 | no | 3 months | 5-ASA, CS |
| Case 19 | M | 33 | active | 6 years 2 months | 5-ASA, AZA |
| Case 20 | F | 20 | no | 11 months | 5-ASA, CS |
| Case 21 | M | 22 | former | 1 years | 5-ASA, IFX |
| Case 22 | M | 33 | active | 4 years 7 months | CS |
| Case 23 | M | 32 | active | 5 years 10 months | 5-ASA, CS, AZA |
5-ASA = Mesalazine; CS = Corticosteroid; IFX = Infliximab; ADA = Adalimumab; AZA = Azathioprine.
Figure 1(a–f). MRE in a 49-year-old woman with CD: severe predominantly fibrotic stricture of the terminal ileum. (a) Coronal fast imaging employing steady state acquisition (FIESTA) image shows wall thickening with noticeable narrowing of the lumen in the terminal ileum (white arrow); note the dilatation (>30 mm) of the upstream bowel loop (white asterisk). (b) Axial and (c) coronal contrast-enhanced fat-suppressed T1-weighted images demonstrate homogeneous enhancement of terminal ileum (white arrows). (d) Axial DW image (b = 800 s/mm2) and (e) corresponding ADC map show the same intestinal segment demonstrating restricted diffusion with high signal intensity (white arrow) on the DWI image and low signal intensity (white arrow) on the ADC map (mean ADC value 0.745 × 10−3 mm2/s). (f) Histopathological section from the ileal stricture: hematoxylin and eosin-stained sample (H&E 10×). CD exhibiting severe fibrosis (FS = 2) and moderate inflammation (AIS = 7): muscular layers dissected by dense fibrotic tissue on the left, mucosal ulceration and moderate inflammatory infiltration on the right.
Figure 2(a–f). MRE in a 19-year-old man with CD: stenosis of the terminal ileum with concomitant inflammation and fibrosis. (a) Coronal T2-weighted image and (b) axial FIESTA image show marked wall thickening of the terminal ileum with luminal narrowing (white arrows). On (c) axial contrast-enhanced fat-suppressed T1-weighted image, the mural thickening of the terminal ileum displays intense mucosal enhancement (white arrow). The same intestinal segment demonstrates high signal intensity on (d) the DW image (b = 800 s/mm2) and low signal intensity on (e) the corresponding ADC map (white arrows) (mean ADC value 1.096 × 10−3 mm2/s), a finding consistent with restricted diffusion. (f) Histopathological section from the ileal stricture: hematoxylin and eosin-stained sample (H&E 10×). CD exhibiting mild/moderate fibrosis (FS = 1) and severe inflammation (AIS = 10): mucosal ulceration and severe inflammatory infiltration on the top; mild/moderate fibrosis, edema and inflammatory infiltration in submucosal layer on the bottom.
Figure 3(a–e). MRE in a 22-year-old man with CD: predominantly inflammatory stricture of the terminal ileum. (a) Coronal FIESTA image shows mural thickening of terminal ileum with stenosis of the lumen (white arrow). (b) Coronal contrast-enhanced fat-suppressed T1-weighted image demonstrates the homogeneous wall enhancement of the affected ileal loop. The same intestinal segment demonstrates restricted diffusion in the form of high signal intensity on (c) the DW image (b = 800 s/mm2) and low signal intensity on (d) the corresponding ADC map (white arrows) (mean ADC value 1.320 × 10−3 mm2/s). (e) Histopathological section from the ileal stricture: hematoxylin and eosin-stained sample (H&E 10×). CD exhibiting absent or minimal fibrosis (FS = 0) and severe inflammation (AIS = 9): mucosal ulceration and intense inflammatory infiltration on the top; edema and intense inflammatory infiltration in the submucosal layer.
Figure 4(a,b). Statistical analysis. Pre-stenotic upstream bowel dilatation (panel a) and ADC (panel b) sorted by fibrosis score. Medians are given with the interquartile range (IQR). ANOVA tests were performed. Bonferroni multiple comparison test: A ≠ C; B ≠ C; D ≠ E ≠ F. ADC = apparent diffusion coefficient.
Figure 5(a,b). Receiver operating characteristic (ROC) analysis. (a) The ROC curve shows that pre-stenotic upstream bowel dilatation has a high accuracy with AUC 0.75 (p < 0.001) for discriminating between none and mild/moderate–severe bowel wall fibrosis. (b) The ROC curve demonstrates that ADC shows a high accuracy with AUC 0.97 (p < 0.001) for discriminating between none and mild/moderate–severe bowel wall fibrosis. ADC = apparent diffusion coefficient, AUC = area under ROC curve.
Qualitative and quantitative MR enterography findings of bowel strictures.
| Thickness (mm) | Luminal Diameter (mm) | T1 Ratio | T2 Ratio | Pattern of Enhancement | ADC × 10−3 mm2/s |
|---|---|---|---|---|---|
| 11 | 25 | 1.928 | 0.291 | layered | 1.473 |
| 11 | 36 | 2.342 | 0.283 | homogeneous | 1.46 |
| 8 | 38 | 2.012 | 0.201 | mucosal | 1.32 |
| 9 | 26 | 1.958 | 0.346 | mucosal | 1.327 |
| 9 | 36 | 1.897 | 0.263 | layered | 1.273 |
| 9 | 80 | 2.062 | 0.138 | homogeneous | 1.247 |
| 10 | 25 | 1.943 | 0.575 | mucosal | 1.177 |
| 12 | 30 | 1.857 | 0.307 | layered | 1.19 |
| 6 | 24 | 1.563 | 0.306 | homogeneous | 1.18 |
| 10 | 39 | 2.464 | 0.268 | mucosal | 1.21 |
| 10 | 20 | 2.059 | 0.365 | layered | 1.233 |
| 8 | 27 | 2.263 | 0.591 | layered | 1.287 |
| 11 | 17 | 1.75 | 0.388 | layered | 1.297 |
| 9 | 58 | 2.305 | 0.213 | homogeneous | 1.183 |
| 9 | 25 | 1.858 | 0.333 | layered | 1.193 |
| 8 | 28 | 1.938 | 0.541 | mucosal | 1.273 |
| 10 | 25 | 2.043 | 0.537 | layered | 0.94 |
| 10 | 53 | 1.876 | 0.349 | mucosal | 0.84 |
| 10 | 28 | 2.828 | 0.245 | mucosal | 0.745 |
| 12 | 26 | 2.222 | 0.266 | layered | 0.955 |
| 14 | 29 | 1.782 | 0.368 | homogeneous | 1.001 |
| 9 | 34 | 1.768 | 0.365 | homogeneous | 0.972 |
| 9 | 25 | 2.002 | 0.474 | mucosal | 1.097 |
ADC = apparent diffusion coefficient.